GlobeNewswire

Graduate Management Admission Council Announces Two New Board Members and Incoming Chairperson of the Board

Dela

Leaders from Berkeley, Duke & Emory business schools bring additional depth and expertise to the organization

RESTON, Va., June 05, 2018 (GLOBE NEWSWIRE) -- The Graduate Management Admission Council (GMAC), a non-profit association of leading global business schools, is pleased to announce two additions to its board of directors and announce the new chairperson of the board. The terms for the new board directors begin on July 1, 2018; the chair position also takes effect as of July 1.

Dr. Bill Boulding, dean of Duke University's Fuqua School of Business, will chair the board. New board members are Erika James, John H. Harland dean of Goizueta Business School, Emory University, and Peter Johnson, assistant dean, full-time MBA Program and admissions, Haas School of Business at the University of California, Berkeley. The term for the board chairperson is two years, four years for board members.

Dr. William "Bill" Boulding is dean of Duke University's Fuqua School of Business. Previously, he held several roles within the school including deputy dean and senior associate dean for programs and associate dean for the Daytime (full-time) MBA program. Dr. Boulding has a passion for helping advance business as a force for good. He served as a member of the World Economic Forum's Council on Values. It has been a privilege for Dr. Boulding to serve, at the invitation of the White House, in developing best practices for how business schools can encourage success for women and working families as part of an initiative with the White House Council on Women and Girls and the Council of Economic Advisers.

"It will be an honor to serve as the chairman of GMAC," said Boulding. "We are in a time of great disruption and transformation in graduate business education. It is essential we maintain relevancy for the world we live in today and I'm excited about the innovations ahead for the industry. I firmly believe in the power of business education in developing leaders who can use business to transform the world for the better."

Erika James became the John H. Harland dean of Goizueta Business School at Emory University in July 2014. A published researcher and award-winning educator with a passion for consulting and speaking, she places an emphasis on what higher education can do to be of service to industry. James is committed to advancing GMAC's mission with a keen interest in providing solutions for schools and candidates to discover and evaluate one another. James believes the success of a student's business education experience depends heavily on finding the right school for them and looks forward to working on the board to further this work. Under James' leadership, Goizueta remains one of the top business schools in the nation with an upward trajectory in student career success and faculty thought leadership. As an educator, James has been instrumental in starting various Executive Education programs, including the Women's Leadership program at Darden Graduate School of Business. James is committed to establishing an equal playing field across gender and race and, in 2014, was honored by the National Diversity Council.

"I'm thrilled to join the GMAC board of directors," said James. "Business, as a field and idea, can do so much more to advance society. GMAC is in the perfect position to influence the future of business education for good and I'm eager to have a role in shaping policy and public opinion with so many great leaders."

Peter Johnson became assistant dean, full-time MBA program and admissions of the Haas School of Business at the University of California, Berkeley, in June 2016. Johnson previously served in Berkeley MBA Admissions for 11 years, first as associate director (1999-2001), then as director of international admissions (2001-2006), and finally as executive director of MBA Admissions from February 2006 until August 2010, when he moved to Europe to serve as vice president for student services at Central European University in Budapest.  Johnson returned to Berkeley as assistant dean of the Haas School in 2016, overseeing academics, student experience, and admissions for the Full-time MBA Program.

Johnson understands the changing needs and priorities of the industry and looks forward to working with the other board members to help address these current challenges. During his time at Haas, he developed and implemented strategy for recruiting applicants worldwide, managed application review and evaluations process for more than 4,000 applicants annually, developed and maintained alumni and student volunteer networks, and worked to diversify the school's recruitment efforts.

"I'm excited about serving on the GMAC Board at a time of significant change in higher education," said Johnson. "GMAC serves an important role in providing data and platforms for business schools across the globe to work together to share best practices for delivering effective and relevant business education aimed at developing leaders.  It's also helped to address issues of access and equity in graduate management education. I look forward to working with fellow board members to help GMAC continue to evolve and provide value to business schools and business students around the world." 

"GMAC relies on its board members to bring unequaled leadership and relevant experience to our organization and our mission," said Sangeet Chowfla, president and CEO of GMAC. "It is extremely gratifying to have such high caliber members of our industry engaged in the work we do to create solutions for schools and candidates, and help more people experience the life-changing benefits of graduate management education."

GMAC would like to thank outgoing board chair, Kate Klepper, associate dean, Graduate Business Programs, D'Amore-McKim School of Business, Northeastern University, whose term as board chair and board member ends June 30. Klepper's experience as chairperson has guided the organization over the past year as we have grown our assessments portfolio and created greater opportunities for candidates and schools to connect. Klepper is passionate about membership engagement and has led the Membership Committee of the board.  

Also leaving the board as of June 30 are Jim Brady, Chief Operating Officer, Grant Thornton LLP, and Ken Freeman, Allen Questrom Professor & Dean, Questrom School of Business, Boston University. GMAC thanks them for their service to our organization and contributions to the education community.

About GMAC:  The Graduate Management Admission Council (GMAC) is a global, non-profit association of leading graduate business schools. Founded in 1953, we are committed to creating solutions for business schools and candidates to better discover, evaluate and connect with each other. We work on behalf of the schools and the graduate management education community, as well as guide candidates on their journey to higher education, to ensure that no talent goes undiscovered.

GMAC provides world-class research, professional development opportunities and assessments for the industry, designed to advance the art and science of admissions. Owned and administered by GMAC, the Graduate Management Admission Test® (GMAT®) is the most widely used graduate business school assessment, recognized by more than 7,000 programs worldwide. Other GMAC assessments include the NMAT by GMAC(TM) exam, for entrance into graduate management programs in India and South Africa, and the Executive Assessment, specifically designed for Executive programs around the world. Our flagship portal for graduate management education resources and information, www.mba.com, receives 14 million visits a year and features the School Finder search tool and Graduate Management Admission Search Service (GMASS), matching candidates and business schools.  

GMAC is based in the United States with offices in the United Kingdom, India, and Hong Kong. To learn more about our work, please visit www.gmac.com.

For information on GMAC's current board members, visit https://www.gmac.com/about-us/board-of-directors.aspx

MEDIA CONTACT:
Tania Hernandez-Andersen
Sr. Director, Corporate Brand Communications
+1 (703) 668-9638 Office
+1 (571) 294-4059 Mobile
thernandez-andersen@gmac.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Graduate Management Admission Council via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum